Atezolizumab Improves On Single-Agent Chemo For Nsclc Not Eligible For Platinum-Containing Regimen

Atezolizumab improves on single-agent chemo for NSCLC not eligible for platinum-containing regimen

IPSOS: 1L atezolizumab vs single-agent chemotherapy in patients with platinum-ineligible NSCLC

#ESMO22 Highlights on first-line atezolizumab in NSCLC not eligible for platinum: The IPSOS study

European Society for Medical Oncology (ESMO)

Results from a phase 3 study of 1L atezolizumab vs single-agent chemotherapy in pts with NSCLC

Single-agent atezolizumab supported for some cisplatin-ineligible mUC patients | Matthew Galsky

Medicine Matters oncology

Atezolizumab for platinum-treated locally advanced or metastatic urothelial carcinoma

Nondriver NSCLC: Adding Pembrolizumab to Platinum-Based Chemotherapy

Targeted Oncology

IMvigor130: atezolizumab +/- platinum-based chemo upfront for advanced urothelial carcinoma

Atezolizumab with chemotherapy improves PFS in squamous NSCLC

Platinum-Based Anti-Tumor Agents

CU Cancer Center

Atezolizumab With Chemotherapy in First-line Treatment of Non-squamous NSCLC

Updated Survival Data From a Trial of Atezolizumab and Chemotherapy for Extensive Stage Small Cell L

Atezolizumab with chemotherapy improves PFS in squamous NSCLC

IMvigor130: Atezolizumab with or without chemotherapy in metastatic urothelial cancer

Locally advanced NSCLC: Combination therapy with targeted and immunotherapy agents

IMpower110: atezolizumab vs chemo in PD-L1–selected NSCLC

Key findings on atezolizumab for mUC from IMvigor130

Platinum-Based Chemo Doublets: Backbone for NSCLC Treatment

GRACE - Global Resource for Advancing Cancer Education

Dr Adwaita Gore | IPSOS Results from a Phase III Study of first line1L atezolizumab vs single agent

CRSF - Cancer Research and Statistic Foundation

Actual Use of Pembrolizumab and Chemotherapy in NSCLC